UroGen Pharma Ltd. (LON:0XOD)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.70B +179.3% |
| Revenue (ttm) | 142.25M +100.3% |
| Net Income | -73.59M |
| EPS | -1.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 24.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,003 |
| Open | 45.90 |
| Previous Close | 46.63 |
| Day's Range | 45.49 - 47.36 |
| 52-Week Range | 15.92 - 49.00 |
| Beta | 1.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal... [Read more]
Financial Performance
In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
UroGen Pharma price target raised to $60 from $50 at Oppenheimer
Oppenheimer raised the firm’s price target on UroGen Pharma (URGN) to $60 from $50 and keeps an Outperform rating on the shares. The firm notes the company reported another strong…
UroGen Pharma price target raised to $58 from $42 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on UroGen Pharma (URGN) to $58 from $42 and keeps a Buy rating on the shares. The firm is raising its…
UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on UroGen Pharma (URGN) to $75 from $45 and keeps a Buy rating on the shares. The firm cites the company’s “massive” Q2…
UroGen Pharma price target raised to $60 from $50 at TD Cowen
TD Cowen raised the firm’s price target on UroGen Pharma (URGN) to $60 from $50 and keeps a Buy rating on the shares. The firm says Zusduri growth accelerated 72%…
UroGen Pharma Earnings Call Transcript: Q2 2026
Q2 2026 revenue surged to $72.5M, led by ZUSDURI's rapid adoption and strong community uptake, while JELMYTO remained stable. Pipeline progress, new patents, and expanded investments support a positive long-term outlook, with profitability expected using current capital.
UroGen Pharma Earnings release: Q2 2026
UroGen Pharma released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
UroGen Pharma Quarterly report: Q2 2026
UroGen Pharma has published its Q2 2026 quarterly earnings report on August 5, 2026.
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 f...
UroGen Pharma Slides: Corporate presentation
UroGen Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
UroGen Pharma price target raised to $42 from $32 at Guggenheim
Guggenheim raised the firm’s price target on UroGen Pharma (URGN) to $42 from $32 and keeps a Buy rating on the shares. The firm is revising some of its estimates…
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
Oppenheimer analyst Leland Gershell raised the firm’s price target on UroGen Pharma (URGN) to $50 from $40 and keeps an Outperform rating on the shares. The firm increased its sales…
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Goldman Sachs raised the firm’s price target on UroGen Pharma (URGN) to $44 from $18 and keeps a Neutral rating on the shares. Gel-based mitomycin generics in NMIBC – Non-Muscle-Invasive…
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
Earlier this morning, the company stated: “UroGen Pharma (URGN) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application no. 18/784,354…
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma announces FDA clearance for UGN-501 IND application
UroGen Pharma (URGN) announced that the FDA cleared the company’s investigational new drug application, or IND, for UGN-501, an investigational oncolytic virus. The IND clearance enables initiation of...
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differen...
UroGen Pharma Transcript: AGM 2026
The meeting reviewed strong product launches and pipeline progress, approved all board proposals, and confirmed a quorum with 75.7% of shares represented. No shareholder questions were submitted, and all proposals passed with final results to be filed within four business days.
UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
ZUSDURI is driving strong growth due to ease of use, robust data, and expanding adoption in community practices. UGN-103 is set for FDA filing in Q3 2024, with approval and market transition expected by 2028. The pipeline includes a phase I oncolytic virus program and plans for broader indications.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic versio...
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced...
UroGen Pharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
ZUSDURI continues to gain traction as a primary therapy for recurrent low-grade intermediate-risk bladder cancer, with strong Q1 revenue growth and increasing physician adoption. The pipeline advances with UGN-103 on track for a 2027 approval and UGN-501 entering phase I trials this year.
UroGen Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The discussion highlighted the proprietary RTGel platform, strong clinical durability for ZUSDURI, and a large market opportunity in NMIBC. Commercial momentum is robust, with revenue growth and expanding community adoption, while successor products and IP strategy aim to extend exclusivity to 2042.
UroGen Pharma reports month results from UTOPIA trial
UroGen Pharma (URGN) announced UGN-103 achieved a 94.5% durability of response at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 for intravesical solution in…